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Abstract
Background and aim: Hepatitis C virus (HCV) and environmental hepatotoxins may
have an indirect influence on health by altering the synthesis and function of hormones,
particularly reproductive hormones. We aimed to evaluate liver diseases and sex steroid
hormones in Egypt, which has the highest prevalence of HCV worldwide.
Methods: We measured markers of hepatitis B virus (HBV), HCV and schistosomiasis
infection as well as liver function in 159 apparently healthy subjects. We measured total
testosterone (T), sex-hormone binding globulin (SHBG) and albumin, and calculated the
free androgen index.
Results: Anti-HCV antibodies were detected in 51% of men and 42% of women. Based on
HCV reverse transcription PCR (RT-PCR) of 44 men and 33 women, 11% of men and 21%
of women showed HCV viremia. There was schistosomiasis in 25% of men and 9% of
women, and mixed HCV viremia and schistosomiasis in 57% of men and 52% of women.
Compared with men with schistosomiasis only (mean 593.3  73.4 ng/dL), T was higher
in men with mixed HCV viremia and schistosomiasis (mean 854.5  47.9 ng/dL; P =
0.006) and men with mixed chronic HCV and schistosomiasis (mean 812.1  43.3 ng/dL;
P = 0.001). Men with mixed chronic HCV and schistosomiasis had also significantly higher
SHBG (mean 57.7  3.9 ng/dL) than males with schistosomiasis only (mean 34.8  SE
4.5 ng/dL; P = 0.0003).
Conclusion: Future investigations should consider that a high prevalence of asymptomatic
liver disease may alter associations between hormone concentrations and chronic disease
etiology.
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Introduction
Liver insults may have an underappreciated effect on the health of
populations by compromising hormone status, particularly sex
steroid hormones. In the liver, cholesterol, the precursor for sex
steroid hormones, undergoes a series of cytochrome P450 enzyme-
mediated conversions to testosterone (T) and estradiol (E2). Also
synthesized in the liver are albumin and sex-hormone binding
globulin (SHBG),1,2 the carrier proteins which bind to the sex
steroid hormones and mediate the amount of bioavailable
hormone. Though androgens can reduce hepatic synthesis of
SHBG and estrogens stimulate SHBG synthesis,2 other factors
also alter binding protein status. Hepatitis infections and aging
increase circulating SHBG concentrations, and obesity, hypothy-
roidism and hyperinsulinemic states decrease circulating SHBG
levels.2
Chronic disease patterns, especially diseases that are hormone
dependent, may differ because of infection exposures that affect
the liver. Gynecomastia has been reported in men with chronic
liver disease, cirrhosis, and hepatocellular carcinoma (HCC).1–4
While E2 and estrone (E1) concentrations are typically normal or
even mildly elevated in affected men, T and dihydrotestosterone
(DHT) levels are decreased, leading to elevated estrogen : test-
osterone ratios.
Chronic disease patterns may be particularly altered in people in
Egypt and the Middle East because of compromised liver status
(and, by extension, altered sex steroid production). Two viral con-
ditions contribute to impaired liver status in Egypt. El-Khoby5 and
colleagues estimated the prevalence of the liver disease-causing
parasite Schistosoma mansoni in five northern Egyptian governor-
ates was 36% and the prevalence of the urinary disease-causing
agent, S. hematobium, was 8% in four southern Egyptian gover-
norates. Further, the majority of the world’s 350–400 million
hepatitis B carriers live in the Middle East, Africa and Asia.6 Prior
to the introduction of HBV vaccination,7 the HBV carrier rate in
Egypt ranged from 18 to 60%.8 Egypt also has the highest
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prevalence of hepatitis C virus (HCV) worldwide, due in part,
although not limited to, the intravenous tartar emetic administra-
tion that had been incorporated into the nationwide anti-
schistosomal campaign in the 1960s to 1980s.5,9 As a result,
approximately 8–10 million Egyptians have been exposed to the
virus and, of these, 5–7 million currently display active viral
infection.10 In studies assessing the prevalence of HCV among
‘apparently healthy’ Egyptian blood donors, the estimated preva-
lence of HCV infection is 15%8 compared with 3% worldwide.11
This pattern of liver compromise may contribute to the unique
patterns of high incidence of young-onset hormone-related cancers
among apparently healthy Egyptian populations. Our research
over the past 10 years has documented the unusually high inci-
dence of young-onset colorectal and pancreatic cancers in
Egypt.12–15 This high incidence of young-onset cancers has not
been linked to specific environmental exposures or hereditary
factors.16,17 Furthermore, recent population-based cancer registra-
tion studies from Egypt have also documented that liver cancer
rates have increased significantly in Egypt and have become the
second most common cancer subsequent to the increasing rates of
HCV infection.18,19 Colorectal, pancreatic and liver cancers are
hormone-dependent cancers, and the increasing and unusual age
distributions of those cancers were the impetus for our conducting
this study.
In anticipation of studies of hormone-dependent chronic dis-
eases, including cancers and heart disease, we evaluated the fre-
quency of impaired liver function in relation to serum and urinary
hormone levels in Egyptians who are ‘apparently healthy’.
Methods
Research site and population
This study was conducted in Fakkous, Egypt (a town with 150 000
individuals) and eight surrounding villages, for a total population
of 450 000 individuals. At the time of our recruitment, the com-
munity medical center was initiating a health education program
and, as a result, had updated the census of the population; this
provided the sampling frame for recruiting our study participants.
This study was conducted in 225 ‘apparently healthy’ males and
females who were randomly selected from a listing of healthy
adult residents aged 18–80 years of age without a diagnosis of
liver disease. Women were excluded for pregnancy, breastfeeding
or use of exogenous hormone therapy (including tamoxifen
therapy and fertility therapy) at the time of recruitment (n = 60), as
well as refusal to venipuncture, leading to a study enrollment of
159 participants (78 males and 81 females). Written or oral consent
was obtained from all subjects prior to enrollment using a protocol
was approved by the University of Michigan Institutional Review
Board and the Cairo University National Cancer Institute (NCI-
Cairo) and Fakkous Cancer Center human subject review
committees.
Data collection
Standardized questions from National Health and Nutrition
Examination Survey (NHANES) family questionnaires20 were
used to gather information about sociodemographic characteris-
tics; smoking and work history; environmental and occupational
exposures; medical history; and menstrual and female reproduc-
tive history. The Arabic translation has been tested for reliability in
previous Egyptian studies.21–23 Following the interview, weight
and height were measured and data used to calculate body mass
index (BMI; kg/m2).
Laboratory methodology
Venipuncture was performed following a minimum 6-h fast and
blood collected in cyrovials with and without preservative. Blood
was taken to the Fakkous Cancer Center, processed, frozen and
transferred to NCI-Cairo where the storage temperature was
reduced to -80°C. The biological specimens were hand-carried on
dry ice to the University of Michigan School of Public Health’s
CLASS laboratory in the USA.
Hormone analysis
Hormone assays were conducted using an ACS-180 automated
analyzer (Bayer Diagnostics, Norwood, MA, USA). Serum T con-
centrations were measured using a modified ACS-180 total test-
osterone assay with increased precision in the lower ranges. The
assay involves competitive binding of a DMAE-labeled testoster-
one derivative to a rabbit polyclonal antitestosterone antibody
premixed with monoclonal antirabbit IgG antibody immobilized
on solid-phase paramagnetic particles. Inter- and intra-assay coef-
ficients of variation were 8.7% and 6.8%, respectively. To assess
the activity of non-bound T, the free androgen index was calcu-
lated: FAI = (total T [ng/dL]  SHBG [nmol/L]). Serum E2 con-
centrations were measured with a modified ACS-180 (E2-6)
immunoassay (Bayer Diagnostics). Inter- and intra-assay coeffi-
cients of variation were 10.2% and 6.4%, respectively, over the
assay range. Estrone (E1) concentrations were measured with an
estrone enzyme immunosorbent assay (RSL/ICN Diagnostics,
Carson, CA, USA). Inter- and intra-assay coefficients were 5.0%
and 3.1%, respectively.
Liver status
Quantitative colorimetric determination was used to assess
albumin levels (Stanbio Albumin LiquiColor Procedure no. 0285;
Stanbio Laboratory, Boerne, TX, USA). Total bilirubin (TBR) and
direct bilirubin (DBR) levels were colorimetrically determined
(Diamond Diagnostics, Holliston, MA, USA). Aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT) concen-
trations were assessed by standard methods (Randox Laboratories,
Antrim, UK). Alkaline phosphatase (AP) was quantitatively deter-
mined by spectrophotometry (Stanbio Alkaline Phosphatase
LiquiColor® Procedure no. 2900; Stanbio Laboratory).
Manufacturer-established inter- and intra-assay coefficients of
variation on three commercial controls for 5 consecutive days for
these assays were 1.7%, 1.2% and 0.9%, and 1.8%, 1.0% and
1.3%, respectively.
Hepatitis B surface antigen (HBsAg) was qualitatively assessed
by chromographic assay (QUALITEST HBsAg One Step Hepati-
tis B Surface Antigen Test Device [Serum/Plasma]; QUALITAS
Bioscience GmbH, Germany) with a relative sensitivity >99.0%, a
relative specificity >96.9% and an accuracy of 98.3%. The quali-
tative HCV Spot Test (ClinPro International LLC, Union City, CA,
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USA) incorporates a reaction between serum anti-HCV antibodies
and membrane-embedded viral proteins in a color response to the
application of a horseradish peroxidase conjugate.
Schistosomal seropositivity was qualitatively assessed by indi-
rect hemagglutination (Laboratoires Fumouze, France), which
does not selectively differentiate between species of S. mansoni,
S. hematobium or S. intercalatum. To test for HBV viremia, PCR
amplification was performed on extracted and purified serum24,25
using 1¥ reaction buffer (50 mmol/L KCl, 10 mmol/L Tris-HCl at
pH 9.0, 1.5 mol/L MgCl2), 0.1% Triton ¥100, 0.2 mmol/L dNTPs,
50 pmol of each primer (primer RB-6A, TTGCCTTCTGAACT
TCTTTCC; primer RB-6B, TCTGCGAGGCGAGGGAGTTCT)
and 2.5 U Taq polymerase (Promega Biotech, Madison, WI,
USA). Thermocycling with a Thermal Cycle 480 (Perkin Elmer,
Waltham, MA, USA) included an initial denaturation at 95°C for
5 min, followed by 35 amplification cycles at 95°C with 1 min for
denaturation, 1 min at 55°C for annealing and 2 min at 72°C for
extension. PCR product (10 mL) was subjected to electrophoresis
on a 2% agarose gel in Tris-acetate EDTA (pH 8.0) stained with
ethidium bromide and visualized under UV transillumination.
For reverse transcription,25–27 a 25 mL reaction mixture contain-
ing 67 mmol/L Tris-HCl (pH 8.8), 17 mmol/L ammonium sulfate,
1 mmol b-mercaptoethanol, 6 mmol/L EDTA (pH 8.0), 0.2 mg
bovine serum albumin (Boehringer, Columbus, OH, USA),
6 mmol/L MgCl2, 25 ng HCV-6 primer, 0.6 mL dNTPs, 11.5 mL
nucleic acid eluate, 200 U Superscript-II RNAase-H reverse tran-
scriptase (Gibco-BRL, Gaithersburg, MD, USA) and 20 U RNAase
inhibitor (Promega Biotech) was subjected to incubation at room
temperature for 5 min, 60 min at 42°C and 5 min at 95°C for RT-II
denaturation. The amplification reaction mixture (100 mL) con-
tained 50 mmol/L Tris-HCl (pH 8.3), 20 mmol/L KCI, 1.5 mmol/L
MgCl2, 1 mg/mL bovine serum albumin, 200 mmol/L dNTPs,
12.5 mL RT reaction mixture, 100 ng of each primer (RB-6A,
RB-6B) and 2.5 U Taq polymerase (Perkin Elmer Cetus). After
denaturation for 5 min at 95°C, the following sequence was used for
30 cycles: denaturation at 95°C for 1 min, annealing at 55°C for
1 min and extension at 72°C for 2 min. PCR product (10 mL) was
electrophoresed in Tris-acetate EDTA (pH 8.0) on a 2% agarose gel
containing ethidium bromide. DNA was transferred to a nitrocellu-
lose membrane in 4 N NaOH buffer, incubated at 80°C for 2–3 h
and hybridized with an internal probe.28
Ultrasonography
Ultrasound examination was undertaken only on subjects who
were serologically positive for HCV or HBV and on the two men
who had elevated SGOT and SGPT levels but were negative for
both HCV and HBV on serological testing. There were 74 HBsAg
and HCV seropositive participants as well as four HCV seronega-
tive enrollees referred for abdominal ultrasound and 67 (86.0%)
presented for examination. Increased hepatic size, periportal thick-
ening, hepatic parenchyma changes, dilated portal vein (>12 mm)
and irregular hepatic contours were used in the sonographic
assessment.
Statistical analysis
Data were entered into the BioDBX version 5 database system and
analyzed using the SAS statistical package.29 Age and BMI data
were log transformed to meet the assumptions of normal residuals
in statistical modeling. Categorical variables (residence and occu-
pation frequencies between men and women) were evaluated using
c2 tests of homogeneity. Student’s t-test was used to test for sex
differences in the transformed hormone and liver biomarkers, and
Fisher’s exact test was used to evaluate HBsAg differences
because of small cell sizes. Linear regression analyses with
dummy variables were used to relate dependent and independent
variables. Odds ratios were used to assess the magnitude of risk of
schistosomal infection, chronic HCV and HCV viremia according
to gender.
Analysis of covariance with orthogonal contrasts was used to
compare mean T, FAI and SHBG differences between three
groups: (i) mixed active or chronic HCV/schistosomal infection to
no infection; (ii) schistosomiasis only to no infection; (iii) and
mixed active or chronic HCV/schistosomal infection to schistoso-
miasis only, while controlling for age and BMI. Type I error was
defined with a P-value < 0.05.
Results
As shown in Table 1, men had greater BMI than women
(26.8  3.0 vs 25.6  3.9; P = 0.01), higher T concentrations than
women (706  251 vs 52  1.2 ng/dL; P < 0.0001), higher FAI
(60  24 vs 3.7  2.9; P < 0.0001) and lower SHBG than women
(48  26 vs 63  34 nmol/L; P = 0.0008).
Serology
Although the population was selected to be apparently healthy and
without a diagnosis of liver disease, there was substantial evidence
of liver disease, shown in Table 2. In apparently healthy men,
potentially impaired liver status could be from mixed anti-HCV
and anti-schistosomal antibodies (n = 32, 41%), schistosomiasis
(n = 24, 31%) or HCV (n = 8, 10%). There were 14 men (18%)
with no evidence of liver impairment (n = 14, 18%). In apparently
healthy women, potentially impaired liver status could be from
mixed infection (n = 20, 25%), schistosomiasis (n = 26, 32%) or
Table 1 Comparison of study characteristics in men and women
Men Women P
Gender n = 78 n = 81 0.81
Age (years) 39.4  10.7 41.5  11.6 0.35
BMI (kg/m2) 26.8  3.0 25.6  3.9 0.01
Testosterone (ng/dL) 706.2  250.5 51.9  1.2 <0.0001
Free androgen index 59.9  23.7 3.7  2.9 <0.0001
Sex-hormone binding
protein (nmol/l)
47.7  26.1 63.0  33.6 0.0008
Residence
Rural 39 (50.0) 32 (39.5) 0.18
Semi-urban 39 (50.0) 49 (60.5)
Occupation
Professional 42 (53.9) 28 (34.6) <0.0001
Nonprofessional 30 (38.5) 15 (18.5)
Retired or unemployed 6 (7.7) 38 (46.9)
Data are expressed as mean  SD, or number (percentage) of partici-
pants, as indicated.
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HCV (n = 14, 17%). There were 21 women with no evidence of
liver impairment (26%). The levels of aminotransferase, albumin
and bilirubin did not differ between the groups, and the observed
differences within the groups were not associated with disease
severity (Table 3).
Ultrasound findings
There were 66 of 77 individuals who presented for abdominal
ultrasound; 24 (15%) displayed hepatomegaly and 15 (9%) sple-
nomegaly. Steatosis, or fatty liver, was observed in 11 (7%) sub-
jects. Periportal thickening, ranging from ‘fine’ to ‘mild’, was
detected in 27 (17%) individuals. Bright and coarse echotexture
was noted in 22 (14%) and 12 (8%), respectively. Evidence of
cirrhosis was seen in six (4%) subjects.
Hormone studies in men
Testosterone, FAI and SHBG values in men are shown in Table 4.
Based on orthogonal contrasts seen in Table 5, men with mixed
chronic HCV and schistosomal infection had statistically signifi-
cantly higher serum T levels (mean 812.1  43.3 ng/dL) than men
with schistosomiasis only (mean 585.1  49.5 ng/dL; P = 0.001).
Further, men with mixed HCV viremia/schistosomal infection had
statistically higher mean T levels compared with men with
schistosomiasis (mean 854.5  47.9 vs 593.3  73.4 ng/dL;
P = 0.006).
Men with mixed chronic HCV and schistosomal infection
had statistically significantly higher SHBG levels (mean
57.7  3.9 ng/dL) than men with schistosomiasis only (mean
34.8  4.5 ng/dL; P = 0.0003), although FAI values were not sta-
tistically different (Table 4). Testosterone levels in men with
abnormal ultrasound characteristics were not significantly differ-
ent from levels in men without abnormalities.
Hormone studies in women
Testosterone, FAI and SHBG for women are shown in Table 4. As
seen in Table 5, there were no statistically significant mean differ-
ences in T or FAI levels in women according to infection subtype.
There was a statistically significant difference in SHBG concen-
trations in women with mixed chronic infection (mean
80.5  7.7 ng/dL) compared with women with schistosomiasis
(mean 58.1  6.7 ng/dL; P = 0.03).
Mean testosterone levels in women with liver cirrhosis
(101  81 pg/mL), coarse echotexture (83  52 pg/mL) or sple-
nomegaly (77  49 pg/mL) by ultrasound were significantly
higher than levels in women without ultrasound abnormalities.
Discussion
There are three primary findings in this evaluation. There was
consistent evidence of frequent liver infections (past and present)
among men and women who were asymptomatic and apparently
healthy at the time of recruitment to the study. Second, hormone
concentrations as well as SHBG levels were different based on the
presence or absence of potential liver impairment. Having HCV
and schistosomiasis constituted a distinct group of participants in
terms of their biochemical and hormonal profiles, particularly
higher testosterone levels. Hepatitis C viral infection may act as a
cofactor modulating the effect of schistosomiasis, which leads to
chronic liver disease, liver fibrosis and appears to have relatively
greater impact on hormone metabolism than viral infection.30 Men
with HCV and schistosomiasis coinfection displayed significantly
higher T and SHBG levels compared with men with either condi-
tion alone. Women with mixed chronic infection had elevated
mean SHBG levels compared with women with schistosomiasis
only.
There are few studies that have characterized hormone values in
liver disease in men and women. A study of Egyptian men with
schistosomiasis with and without cirrhosis reported significantly
reduced serum T and luteinizing hormone (LH) concentrations in
men characterized as ‘infertile’ cirrhotics with S. mansoni and
S. hematobium coinfection compared with ‘infertile’ males with
either concomitant infection or S. mansoni or S. hematobium
infection. Significant differences were not observed when they
were compared with normal controls or ‘fertile’ men with mixed
S. mansoni and S. hematobium coinfection.31 In contrast, a study
observed no significant difference in serum T concentration in 38
Brazilian men singly infected with S. mansoni compared with
controls.32
High testosterone levels in participants with concomitant HCV
and schistosomiasis is consistent with studies from China and







P OR (95% CI)
Chronic infection
Anti-HCV antibody only 8 (10) 14 (17) 0.12 –
Mixed infection 32 (41) 20 (25)
Schistosomiasis only 24 (31) 26 (32)
No infection 14 (18) 21 (26)
Active infection (viremia)
HCV viremia only 5 (11) 7 (21) 0.11 –
Mixed infection 25 (57) 17 (52)
Schistosomiasis only 11 (25) 3 (9)
No infection 3 (6) 6 (18)
Anti-HCV antibody
Positive 40 (51) 34 (42) – 1.5 (0.78–2.7)
Negative 38 (49) 47 (58)
HBsAg
Positive 1 (1) 0 (0) 0.49 –
Negative 77 (99) 81 (100)
Anti-schistosomal antibody
Positive 56 (72) 46 (57) – 1.9 (1.0–3.7)
Negative 22 (28) 35 (43)
HCV viremia†‡
Positive 30 (68) 24 (73) – 0.80 (0.30–2.2)
Negative 14 (32) 9 (27)
HBV viremia
Positive 0 (0) 0 (0) NA
Negative 1 (100) 0 (0)
†Missing RT-PCR report for one anti-HCV antibody positive female.
‡Includes four subjects who, while negative on HCV antibody screening,
were evaluated for viremia based on elevated liver transaminases
(n = 2), self-reported HCV (n = 1) and HBsAg on HBV screening (n = 1).
NA, not applicable.
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Table 3 Markers of hepatobiliary functions by gender and type of infection
Measure Men (Intergender) (a = 0.05)
Mean  SD
Women (Intragender)
(a = 0.05) Mean  SD
(Intergender) P (Intragender) P
Chronic infection
Albumin
Mixed infection 4.2  0.45 4.1  0.28 0.1043 M: 0.6115
Schistosomiasis only 4.3  0.37 4.4  0.32 W: 0.0572
No infection 4.3  0.24 4.2  0.30
Direct bilirubin
Mixed infection 0.18  0.060 0.14  0.029 0.3903 M: 0.7445
Schistosomiasis only 0.15  0.055 0.15  0.12 W: 0.3430
No infection 0.14  0.033 0.18  0.16
Total bilirubin
Mixed infection 0.74  0.15 0.60  0.13 0.2728 M: 0.6354
Schistosomiasis only 0.64  0.16 0.58  0.16 W: 0.2122
No infection 0.63  0.12 0.67  0.31
SGPT
Mixed infection 17.0  10.6 12.2  4.6 0.7323 M: 0.0757
Schistosomiasis only 16.6  11.5 8.4  5.3 W: 0.0745
No infection 11.6  8.9 10.0  5.1
SGOT
Mixed infection 15.9  7.9 12.9  4.9 0.8921 M: 0.7034
Schistosomiasis only 14.2  7.1 9.9  3.4 W: 0.6416
No infection 12.8  6.5 10.0  3.2
Alkaline phosphatase
Mixed infection 12.7  4.4 11.2  3.2 0.6530 M: 0.4821
Schistosomiasis only 12.0  2.6 9.1  2.4 W: 0.8063
No infection 11.0  2.8 8.9  1.4
Active infection
Albumin
Mixed infection 4.2  0.42 4.1  0.28 0.9870 M: 0.1934
Schistosomiasis only 4.0  0.52 4.4  0.00 W: 0.0167
No infection 4.3  0.49 3.9  0.24
Direct bilirubin
Mixed infection 0.17  0.047 0.14  0.029 0.4396 M: 0.5284
Schistosomiasis only 0.15  0.055 0.14  0.044 W: 0.2814
No infection 0.19  0.023 0.16  0.022
Total bilirubin
Mixed infection 0.72  0.14 0.60  0.13 0.7475 M: 0.7102
Schistosomiasis only 0.78  0.1 0.58  0.16 W: 0.1408
No infection 0.78  0.19 0.68  0.059
SGPT
Mixed infection 16.6  8.7 12.5  4.5 0.4946 M: 0.2851
Schistosomiasis only 21.7  17.4 8.0  2.0 W: 0.0930
No infection 14.0  7.2 13.7  5.2
SGOT
Mixed infection 15.4  6.4 13.1  4.8 0.8100 M: 0.3616
Schistosomiasis only 18.5  12.0 9.0  1.0 W: 0.0877
No infection 13.3  3.1 14.8  5.4
Alkaline phosphatase
Mixed infection 12.3  3.1 11.5  3.6 0.2455 M: 0.3214
Schistosomiasis only 14.2  6.7 10.6  2.2 W: 0.9940
No infection 11.9  2.0 10.7  1.2
Chronic infection: mixed infection (40 M, 34 W), schistosomiasis only (24 M, 26 W) and no infection (14 M, 21 W); Active infection: mixed infection
(30 M, 24 W), schistosomiasis only (11 M, 3 W) and no infection (3 M, 6 W). Mixed infection: HCV infection only plus mixed HCV/schistosomiasis
infection; Schistosomiasis only: schistosomiasis infection only; No infection, no HCV and no schistosomiasis infection.
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Taiwan. In those studies, high testosterone levels were identified in
follow-up studies of chronic HCV and HBV patients who subse-
quently developed HCC.33,34
Previous studies reported high testosterone levels in follow-up
studies of chronic HCV patients who subsequently developed
hepatocellular carcinoma (HCC). For example, a nested case–
control study of HCC cases based on a follow-up of a cohort of
18 244 men in Shanghai, China,33 revealed higher testosterone
levels in HCC cases than controls. After an average follow up of
5.3 years, HCC cases had significantly higher mean level of test-
osterone than controls (570 ng/dL vs 485 ng/dL in cases and con-
trols, respectively; P = 0.0005). A study in Taiwan of 9691 male
adults reported that elevated testosterone levels were associated
with increased risk of HCC after adjustment for HBV, HCV and
other risk factors. Men with testosterone levels in the upper tertile
had more than four times higher risk for HCC than men with
testosterone levels in the middle and lower tertiles (OR = 4.1; 95%
CI, 1.3–13.2; P = 0.016). High testosterone levels were associated
with HCC in men in China through androgen signaling
mechanisms.34,35
These study results suggest that testosterone levels could be
used as a marker in screening; future studies could capitalize on
the results of this study and consider using hormone profile as a
screening marker in this population.
Additional studies of Egyptian people with chronic HCV infec-
tion and schistosomiasis who exhibit high testosterone levels are
needed to see if these higher hormone values present at early-stage
hepatic carcinogenesis and if they impact disease progression.
Several studies from Egypt have shown that concomitant chronic
HCV infection and schistosomiasis present a greater risk for HCC
than the independent risk of HCV, HBV or schistosoma alone.36–38
This study has strengths, including our access to a representative
sample of an apparently healthy population in one of the countries
with the highest prevalence of HCV. To our knowledge, this is the
first report to address biochemical and hormonal profiles in appar-
ently healthy asymptomatic participants where multiple causes of
Table 4 Serum testosterone, free androgen index and SHBG levels according to type of infection and gender




Men P (M)† Women P (W)‡
Chronic infection
Testosterone (ng/dL)
Anti-HCV antibody only 727.5  192.0 64.0  31.1 8 0.3113 14 0.5200
Mixed infection 806.6  251.8 48.3  21.5 32 20
Schistosomiasis only 586.9  216.9 46.5  19. 24 26
No infection 668.9  254.0 54.0  29.3 14 21
Free androgen index
Anti-HCV antibody only 52.7  21.8 4.3  4.3 8 0.3490 14 0.9123
Mixed infection 53.5  21.2 2.7  1.9 32 20
Schistosomiasis only 64.1  24.1 3.5  2.1 24 26
No infection 71.4  26.1 4.4  3.5 14 21
SHBG (nmol/L)
Anti-HCV antibody only 56.0  28.8 68.2  26.1 8 0.8176 14 0.3313
Mixed infection 59.5  27.7 79.1  42.6 32 20
Schistosomiasis only 34.8  14.6 58.7  33.3 24 26
No infection 38.4  24.4 49.7  22.0 14 21
Active infection
Testosterone
Anti-HCV antibody only 734.6  237.8 64.3  16.4 5 0.1255 7 0.9452
Mixed infection 850.4  232.0 51.6  21.4 25 17
Schistosomiasis only 602.8  243.8 29.4  9.9 11 3
No infection 715.7  124.6 65.9  46.3 3 6
Free androgen index
Anti-HCV antibody only 50.3  17.6 5.1  5.4 5 0.9030 7 0.3863
Mixed infection 53.1  15.7 2.9  1.9 25 17
Schistosomiasis only 56.9  28.6 1.9  1.8 11 3
No infection 56.6  31.7 3.8  3.2 3 6
SHBG (nmol/L)
Anti-HCV antibody only 56.6  31.2 64.2  25.2 5 0.4200 7 0.7024
Mixed infection 61.1  26.3 78.1  41.3 25 17
Schistosomiasis only 44.8  29.2 84.6  59.8 11 3
No infection 55.0  30.9 69.9  30.4 3 6
Chronic infection: mixed infection (40 M, 34 W), schistosomiasis only (24 M, 26 W) and no infection (14 M, 21 W); Active infection: mixed infection
(30 M, 24 W), schistosomiasis only (11 M, 3 W) and no infection (3 M, 6 W). ; †Comparison between the four values of men in the category using
ANOVA; ‡Comparison between the four values of women in the category using ANOVA. SHBG, sex-hormone binding globulin.
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Table 5 Orthogonal contrasts to show differences between testosterone, free androgen index and SHBG values in subtypes of infection by gender




0 1 -152.4 80.4 0.06
0 2 74.6 82.7 0.37
1 2 227.0 65.9 0.00
Free androgen index Chronic Chronic
0 1 9.5 6.7 0.16
0 2 1.7 6.9 0.81
1 2 -7.8 5.5 0.16
SHBG Chronic Chronic
0 1 -15.2 7.3 0.16
0 2 7.8 7.5 0.30
1 2 22.9 6.0 0.00
Women
Testosterone Chronic Chronic
0 1 2.8 7.1 0.70
0 2 8.3 6.7 0.22
1 2 5.5 6.9 0.43
Free androgen index Chronic Chronic
0 1 1.6 0.82 0.06
0 2 0.96 0.76 0.22
1 2 -0.60 0.79 0.45
SHBG Chronic Chronic
0 1 -31.2 10.6 0.16
0 2 -8.9 9.9 0.37




0 1 -138.2 147.9 0.36
0 2 123.0 158.7 0.44
1 2 261.2 88.9 0.01
Free androgen index Viremia Viremia
0 1 10.8 12.1 0.38
0 2 4.1 13.0 0.75
1 2 -6.7 7.3 0.36
SHBG Viremia Viremia
0 1 -13.5 16.4 0.41
0 2 6.0 17.6 0.74
1 2 19.5 9.9 0.06
Women
Testosterone Viremia Viremia
0 1 16.7 14.1 0.25
0 2 39.9 20.7 0.07
1 2 23.2 18.3 0.22
Free androgen index Viremia Viremia
0 1 0.97 1.1 0.40
0 2 2.1 1.7 0.21
1 2 1.2 1.5 0.44
SHBG Viremia Viremia
0 1 -9.5 21.1 0.66
0 2 -14.5 30.9 0.64
1 2 -5.0 27.4 0.86
Chronic infection: mixed infection (40 M, 34 W), schistosomiasis only (24 M, 26 W) and no infection (14 M, 21 W); Active infection: mixed infection
(30 M, 24 W), schistosomiasis only (11 M, 3 W) and no infection (3 M, 6 W). SHBG, sex-hormone binding globulin.
Chronic: 0, no infection; 1, mixed chronic HCV and schistosomiasis infection; 2, schistosomiasis only.
Viremia: 0, no infection; 1, mixed HCV viremia and schistosomiasis infection; 2, schistosomiasis only.
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liver disease exist. However, we could not explore the true capacity
of the binding of testosterone to its receptor. The relatively small
sample size in this population with multiple subgroups limited the
power to detect some associations. Neither a causal relationship
between HBV, HCV, schistosomiasis and liver disease nor a tem-
porality was assessed, as a limitation of the cross-sectional nature
of the study; however, the important results of this study would set
the stage for a future large-scale study to test the hypothesis of
testosterone level modulation in chronic diseases by HCV and
schistosomal infection.
In summary, we observed marked biochemical and hormonal
changes of androgen profile among HCV–schistosoma-infected
participants who were asymptomatic and apparently healthy at the
time of recruitment in the study in Egypt. Men with chronic HCV
and schistosomiasis coinfection displayed significantly higher tes-
tosterone and SHBG levels compared with men with either con-
dition. Future investigations should explore the association
between chronic disease etiology and hormonal imbalance in
populations with a high prevalence of asymptomatic liver disease.
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